Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Previously Published Works bannerUCLA

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

  • Author(s): Skinner-Adams, Tina S;
  • Butterworth, Alice S;
  • Porter, Kimberly A;
  • D'Amico, Ronald;
  • Sawe, Fred;
  • Shaffer, Doug;
  • Siika, Abraham;
  • Hosseinipour, Mina C;
  • Stringer, Elizabeth;
  • Currier, Judith S;
  • Chipato, Tsungai;
  • Salata, Robert;
  • Lockman, Shahin;
  • Eron, Joseph J;
  • Meshnick, Steven R;
  • McCarthy, James S
  • Editor(s): Tripathy, Srikanth Prasad
  • et al.
Abstract

HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View